Inhibition of cell proliferation and MAP Kinase and Akt pathways in oral squamous cell carcinoma by genistein and biochanin A

Evidence-based Complementary and Alternative Medicine

Volumn 7, Issue 3, 2010, Pages 351-358

  Johnson, Tara L ^a   Lai, Maria B ^a   Lai, James C K ^a   Bhushan, Alok ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

cancer prevention; cell signalling; isoflavones; oral cancer

Indexed keywords

BIOCHANIN A; DAIDZEIN; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; HYPOTHESIS; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 77953843784     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nen011     Document Type: Article

References (40)

1. Mignogn MD, Fedele S, Russo LL. The world cancer report and the burden of oral cancer. Eur J Cancer Prev 2004;13:139-142
2. Scheer M, Kuebler AC, Zoller JE. Chemoprevention of oral squamous cell carcinomas. Onkologie 2004;27:187-193
3. Lippman SM, Sudbo J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005;23:346-356 (Pubitemid 46206883)
4. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 2006;6:1111-1118 (Pubitemid 44203388)
5. Walker DM, Boey G, McDonald LA. The pathology of oral cancer. Pathology 2003;35:376-383
6. Wong DT, Todd R, Tsuji T, Donoff RB. Molecular biology of human oral cancer. Crit Rev Oral Biol Med 1996;7:319-328
7. Scaltriti M, Baselga J. The epidermal growth factor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-5272 (Pubitemid 44497237)
8. Arvind R, Shimamoto H, Momose F, Amagasa T, Omura K, Tsuchida N. A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation. Int J Oncol 2005;27:1499-1504
9. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
10. Amornphimoltham P, Sriuranpong V, Patel V, Benevides F, Conti CJ, Sauk J, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004;10:4029-4037
11. Powis G, Ihle N, Kirkpatrick DL. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 2006;12:2964-2966
12. Cheng JQ, Linsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/ PKB pathway: molecular targets for cancer drug discovery. Oncogene 2005;24:7482-7492
13. Lim J, Kim JH, Paeng JY, Kim MJ, Hong SD, Lee JI, et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 2005;58:1199-1205
14. Pietras RJ, Weinberg OK. Antiangiogenic steroids in human cancer therapy. Evid Based Complement Alternat Med 2005;2:49-57.
15. Vieira JRC, de Souza IA, do Nascimento SC, Leite SP. Indigofera suffruticosa: an alternative anticancer therapy. Evid Based Complement Alternat Med 2007;4:355-359
16. Branca F, Lorenzetti S. Health effects of Phytoestrogens. Forum Nutr 2005;57:100-111
17. Nakashima S, Koike T, Nozawa Y. Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses. Mol Pharmacol 1991;39:475-480
18. Azuma Y, Onishi Y, Sato Y, Kizaki H. Effects of protein tyriosine kinase inhibitors with different modes of action on topoisomerase activity and death of IL-2-dependent CTLL-2 cells. J Biochem 1995;118:312-318
19. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Shibuya M. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5595
20. Shon YH, Park SD, Nam KS. Effective chemopreventive activity of genistein against human breast cancer cells. J Biochem Mol Biol 2006;39:448-451
21. Wang J, Eltoum IE, Lamartiniere CA. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol Cell Endocrinol 2004;219:171-180
22. Myoung H, Hong SP, Yun PY, Lee JH, Kim MJ. Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci 2003;94:215-220
23. Gerhauser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knaft J, et al. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res 2003;523-524:163-172
24. Alhasan SA, Ensley JF, Sarkar FH. Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int J Oncol 2000;16:333-338
25. Hiraishi Y, Wada T, Nakatani K, Negoro K, Fujita S. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol Oncol Res 2006;12:151-160
26. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 2004;546:121-165
27. Ghosh S, Munshi HG, Sen R, Linz-McGillem LA, Goldman RD, Lorch J, et al. Loss of adhesion-regulated proteinase production is correlated with invasive activity in oral squamous cell carcinoma. Cancer 2002;38:468-474
28. Alhasan SA, Ensley JF, Sarkar FH. Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int J Oncol 2000;16:333-338
29. Davis JN, Kucuk O, Sarkar FH. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol Carcinog 2002;34:91-101.
30. Su SJ, Yeh TM, Lei HY, Chow NH. The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 2000;6:230-236
31. Chun KH, Kosmeder JW, Sun S, Pezzuto JM, Lotan R, Hong WK, et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003;95:291-302.
32. Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 2006; 319:991-997
33. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 2005;31:151-174
34. Mishima K, Yamada E, Masui K, Shimokawara T, Takayama K, Sugimura M, et al. Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma. Mod Pathol 1998;11:886-891 (Pubitemid 28440886)
35. Mukhopadhyay S, Munshi HG, Kambhampati S, Sassano A, Platanias LC, Stack MS. Calcium-induced matrix metalloproteinase 9 gene expression is differentially regulated by ERK1/2 and p38 MAPK in oral keratinocytes and oral squamous cell carcinoma. J Biol Chem 2004;279:33139-33146
36. Gopalakrishnan A, Xu CJ, Nair SS, Chen C, Hebbar V, Kong AN. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostrate cancer PC3 cells. Arch Pharm Res 2006;29:633-644
37. Akimoto T, Nonaka T, Ishikawa H, Sakurai H, Saitoh JI, Takahashi T, et al. Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways. Int J Radiat Oncol Biol Phys 2001;50:195-201.
38. Cao F, Jin TY, Zhou YF. Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene. Biomed Environ Sci 2006; 19:35-41.
39. Banerjee S, Zhang Y, Ali S, Bhuyian M, Wang Z, Chiao PJ, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro an in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005;65:9064-9072
40. Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr 2003;133:2367-2376